Alerta

一种极性带电残基工程化的MspA纳米孔及其制备方法和应用

Resumen de: CN121758562A

0001 本发明提供一种极性带电残基工程化的MspA纳米孔，所述MspA纳米孔以突变体M2 MspA纳米孔为基础，针对其收缩区的N91氨基酸位点进行定点突变，突变后的氨基酸包括天冬氨酸、精氨酸、谷氨酸。纳米孔的制备方法包括以下步骤：S1、将进行定点突变后的突变体M2 MspA的基因插入质粒；S2、将重组质粒转化至大肠杆菌感受态细胞中，培养，将培养体系冷却后加入IPTG，继续培养，诱导目标蛋白的表达；S3、收集菌体，加入裂解缓冲液，加热处理后随即冷却，离心，收集上清，利用镍亲和层析纯化，即得。本发明提供的MspA纳米孔可以实现10种PTM的单分子检测，还能区分异构体，识别准确率超过98%，为复杂修饰蛋白组学研究提供了新型工具。

葫芦巴碱的药物应用及其筛选方法

Resumen de: CN121754543A

本发明涉及葫芦巴碱的药物应用及其筛选方法，所述白细胞介素‑8拮抗剂通过如下筛选方法获得：S1、定制特定的白细胞介素‑8作为靶标，定制FDA药物库作为药物分子库，备用；S2、使用靶标在药物分子库中进行高通量分子筛选，从药物分子库中筛选出能与靶标相结合的特定的药物分子；S3、检测所述特定的药物分子对所述靶标作用的拮抗效果，对所述特定的药物分子进行拮抗所述靶标的剂效评估。

一种基于数字PCR的单分子蛋白检测方法

Resumen de: CN121759570A

0001 本发明涉及数字PCR检测技术领域，尤其涉及一种基于数字PCR的单分子蛋白检测方法。本发明的检测方法是将数字PCR与免疫PCR融合，通过磁珠偶联捕获抗体，捕获抗原后与通过链霉亲和素‑生物素偶联核酸片段的检测抗体结合，形成双抗夹心结构，利用数字PCR扩增放大荧光信号，计算得到待测样本的目标蛋白浓度，从而实现单分子蛋白的定量检测，检测限达到0.395fg/ml。本发明检测方法定量准确，灵敏度优异，能够极大降低检测成本，提高检测效率，简化检测流程，减少对设备精度的高要求。

Tau蛋白289磷酸化位点特异性结合蛋白、阿尔兹海默症诊断试剂盒及其制备方法与应用

Resumen de: CN121758610A

本申请属于免疫检测技术领域，具体涉及Tau蛋白289磷酸化位点特异性结合蛋白、阿尔兹海默症诊断试剂盒及其制备方法与应用。本申请提供Tau蛋白289磷酸化位点特异性结合蛋白其具有特定的CDRs，该特异性结合蛋白通过特异性识别p‑tau‑289位点，在AD早期阶段即表现出显著的丰度改变，与p‑tau‑181和p‑tau‑217相比，在鉴别阿尔兹海默病与非AD神经退行性疾病方面表现出更高的特异性，能够在临床前阶段实现精准识别，为超早期干预提供关键时间窗口。

バイオマーカーの多重検出のためのシステムおよび方法

Resumen de: CA2106077A1

2106077 9216902 PCTABS00016 A data processing pension plan monitor (40) is directed specifically to the management and controlled access of pensionbacked credit (AC). This system permits pension plan participants to establish a line of credit (LOC), based on their vested interest in a sponsored pension plan (10). This LOC is thereafter systematically applied to a plurality of account (80, 90), each permitted selected credit card (90) and/or check writing privileges. The charges associated with the credit accessed are paid back to the pensioner, thereby retaining certain tax deferred privileges while permitting access to the accumulated funds.

基于尿UC5B-9检测的通过局部补体抑制对补体介导的疾病进行的靶向治疗

Resumen de: WO2025019486A2

Provided is the use of urinary C5b-9 (uC5b-9) as a highly accurate and superior biomarker well correlated with complement activity in local tissues affected by complement-mediated diseases (e.g., those with a kidney damage component). The biomarker is useful, for example, in treating and/or monitoring such complement-mediated diseases, using complement inhibitors targeted to such local tissues affected by the diseases, without systemic complement inhibition.

NAT10–ac4C–线粒体–acetyl-CoA调控轴在诊治线粒体功能障碍及相关代谢性疾病中的应用

Resumen de: CN121737288A

0001 本发明公开了一种NAT10–ac4C–线粒体–acetyl‑CoA调控轴在诊治线粒体功能障碍及相关代谢性疾病中的应用，属于生物技术领域。该调控轴在生理状态下系统性地调控核编码线粒体基因表达，维持代谢稳态；本发明还提供了该调控轴的生物标志物组合包括NAT10相关指标、核编码线粒体基因mRNA的ac4C修饰水平及乙酰辅酶A水平，可用于线粒体功能障碍及相关代谢性疾病的诊断与预后评估；同时，本发明还提供了基于该调控轴的药物筛选方法、治疗方法及相关药物应用，实现了对线粒体功能障碍相关疾病的系统性诊断与普适性治疗，具有重要的临床转化价值。

一种用于帕金森病诊断的生物标志物组合及基于LINC00467/miR-494-3p/CYCS轴的诊疗应用

Resumen de: CN121737291A

本申请公开了生物医药技术领域的一种用于帕金森病诊断的生物标志物组合及基于LINC00467/miR‑494‑3p/CYCS轴的诊疗应用。本发明提供了以LINC00467、miR‑494‑3p、CYCS为核心的PD早期诊断生物标志物组合，以及以该调控轴为靶点的PD治疗方案和药物开发方向。该发明解决了现有PD诊断特异性低、依赖临床症状，且治疗靶点匮乏、机制不清的技术问题，具有重要的临床应用价值和产业化前景。

体液细胞外囊泡膜蛋白在制备诊断青光眼疾病产品中的用途

Resumen de: CN121741201A

本发明公开了一种体液细胞外囊泡膜蛋白在制备诊断青光眼疾病产品中的用途，外囊泡膜蛋白选自外囊泡上的Tau蛋白和/或GFAP蛋白，本发明首次提出通过特异性膜蛋白（GLAST和L1CAM）捕获外周血中NDEVs，从而更精准地反映中枢神经系统与视网膜组织的病理变化。

一种用于检测Tau-441蛋白的新型高灵敏度电化学免疫传感器

Resumen de: CN121741165A

本发明公开了一种基于纳米材料协同放大效应的高灵敏度Tau‑441电化学免疫传感器及其制备方法与应用。该传感器以丝网印刷电极（SPE）为基底，采用PEDOT:PSS/MWCNTs‑COOH纳米复合材料修饰工作电极作为传感平台，利用其大比表面积和优异导电性促进电子转移。同时，制备金修饰磁性纳米粒子（Fe3O4@AuNPs）作为信号探针，结合了Fe3O4的磁分离富集功能与金纳米粒子的生物相容性及催化活性。本发明采用均相反应模式构建夹心免疫复合物，有效降低了传质阻力并缩短了检测时间。该传感器对阿尔茨海默病标志物Tau‑441具有极低的检测限（19.68fgmL‑1）和宽线性范围，特异性强且稳定性好，适用于人血浆样本的早期快速筛查。

PAD4 조정제의 시트룰린화 및 활성을 평가하는 방법

Resumen de: US2018099049A1

Stable lyophilized therapeutic protein compositions and their methods of manufacture are provided. Specifically, the use of water as a solid cake plasticizer and protein stabilizer is described. Also, the inclusion of a multicomponent stabilizer comprising a larger molecular entity and a smaller molecular entity is described. Also, the inclusion of post-drying annealing under certain conditions improves protein stability. Proteins are predicted to remain stable over 24 months at 25° C.

ZIF8基自增强复合材料、电化学发光-电化学适配体传感器及其制备方法、应用

Resumen de: CN121736304A

0001 本发明公开一种ZIF8基自增强复合材料、电化学发光‑电化学适配体传感器及其制备方法、应用，利用一步自组装法设计制备了一种新型自增强电化学发光复合材料（Ru‑N@ZIF8），因其将发光体（Ru(dcbpy)<3>2+ ）和共反应剂（NGQDs）同时包裹到同一个材料（ZIF8）中，缩短电子转移距离，显著提升了电化学发光效率。基于Ru‑N@ZIF8的自增强电化学发光‑电化学双模适配体传感器用于检测啶虫脒，电化学发光和电化学的线性范围均为1 pM~100 nM，检出限分别为0.046 pM和0.050 pM。本发明的传感器表现出较好的选择性，具有较好的重现性和稳定性。

用于治疗突触核蛋白病的药剂、用途和方法

Resumen de: WO2017009312A1

The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.

一种用于疾病的疗效评估方法、系统和相关生物标志物

Resumen de: CN121737286A

本公开提供了一种用于疾病的疗效评估方法、系统和相关生物标志物，方法包括：获取第一状态的第一检测物，检测所述第一检测物中的生物标志物；获取第二状态的第二检测物，检测所述第二检测物中的生物标志物；比较所述第一检测物中的生物标志物和所述第二检测物中的生物标志物，得到比较结果；根据所述比较结果，确定评估结果。

作为子宫内膜异位症的生物标志物的血清EphA1

Resumen de: WO2025026908A1

The present invention relates to methods of diagnosing whether a subject has endometriosis, uterine/pelvic pathology and/or endometriosis and/or uterine/pelvic pathology associated neuropathic pain, to methods of determining the therapeutic effect of a treatment regimen for endometriosis, uterine/pelvic pathology and/or endometriosis and/or uterine/pelvic pathology associated neuropathic pain, and methods of monitoring endometriosis, uterine/pelvic pathology and/or endometriosis and/or uterine/pelvic pathology associated neuropathic pain progression in a subject, by determining the amount or concentration of EphA1 in a sample of the subject, and comparing the determined level to a reference value.

人Tau蛋白抗体及应用

Resumen de: CN121736098A

本发明公开了一种人Tau蛋白抗体及应用，该抗体的轻链CDR1、CDR2和CDR3氨基酸序列依序如SEQ ID NO：1~3所示，重链CDR1、CDR2和CDR3氨基酸序列依序如SEQ ID NO：4~6所示。该人Tau蛋白抗体能够特异性结合磷酸化及非磷酸化人Tau蛋白，亲和力强、稳定性高，EC50低于3.6ng/mL。基于该抗体制备的酶联免疫检测试剂盒具有灵敏度高的特点，检测灵敏度小于19.5 pg/mL，线性检测范围为0‑20000 pg/mL，并且特异性强、准确性好，能够实现准确、高通量地检测样品中的Tau蛋白含量，具有优异的应用前景。

A NOVEL AND IMPROVED METHOD OF DIFFERENTIATING INFECTION FROM INFLAMMATION

Resumen de: AU2024327213A1

A method of determining a health status of an individual, the method comprising the steps of assaying a biological sample from the individual for the positive expression of SAA1 and/or SAA2, and wherein the positive expression of the SAA1 and/or SAA2 above or below a threshold expression level in a control sample correlates with the health status of the individual.

A Method for Determining a Chemotypic Profile

Resumen de: AU2026201729A1

The present invention relates generally to methods for determining the chemotypic profile of cannabis plant material, including uses thereof. ar a r

Methods and assays for modulating gene transcription by modulating condensates

Resumen de: AU2026201771A1

Abstract Described herein are compositions and methods for modulating gene regulation by modulating condensate formation, composition, maintenance, dissolution and regulation. Abstract ar a r

METHODS OF DIAGNOSING ACUTE CIRCULATORY FAILURE

Resumen de: US20260086063A1

0000 Circulatory failure generates hypoxia and leads to accumulation of reductive species in tissue and circulatory failure monitoring tools are needed but rare. Cardiopulmonary bypass (CPB) is known to promote brief circulatory failure during its initiation. In the present study, the Inventors demonstrate a correlation between whole blood redox potential and circulatory failure during (CPB). They made a prospective study with 17 patients eligible for cardiac surgery with cardiopulmonary bypass. They demonstrated a frank reduction of the whole blood redox potential during circulatory failure during the initiation of CPB. They also demonstrated that they were able to classify patients in 3 groups, one of them presenting an unfavorable post-operative outcome. Accordingly, the present invention relates to a method of diagnosing acute circulatory failure in a patient comprising determining the level of redox potential in a sample obtained from said patient, wherein the level of redox potential indicates whether the patient suffers or not from an acute circulatory failure.

NEW SYNTHETIC DRUGS FOR TREATING ALZHEIMER'S DISEASE

Resumen de: US20260083826A1

The present invention aims to provide a novel agent for treating Alzheimer's disease, a method for treating Alzheimer's disease, a method for screening for a candidate substance for a therapeutic drug for Alzheimer's disease, and the like. The present invention is a prophylactic and/or therapeutic agent for Alzheimer's disease comprising a peptide corresponding to dynamin 1. The peptide preferably corresponds to dynamin 1-pleckstrin-homology domain or dynamin 1-proline rich domain. In addition, the peptide is preferably encapsulated in nano-particles or linked to a peptide sequence that improve delivery of the peptide into the brain.

METHODS TO DETERMINE DRUG TARGET RESIDENCE TIME AND TO SELECT BEST DRUG-TARGET CANDIDATES

Resumen de: US20260086093A1

0000 The present invention relates to methods for the determination of the residence time between at least one Target and at least one Ligand, optionally in their native biological context, using limited proteolysis e.g., combined with selected reaction monitoring, parallel reaction monitoring, data-independent acquisition (DIA), including Sequential Windowed Acquisition of All Theoretical Fragment Ion Mass Spectra (SWATH) methods and the like.

CARTRIDGE-BASED AUTOMATED RAPID TEST ANALYZER

Resumen de: US20260086086A1

0000 Embodiments may include a rapid test device that provide rapid detection of substances, including those involved in pathogen infection, for example, using Microscale Affinity Chromatography (MAC), indirect ELISA, and optical molecular sensing technology. For example, in an embodiment, an apparatus may comprise a loading bay disposed on the apparatus to receive a cartridge, a door disposed on the apparatus to cover the loading bay, a plurality of prongs disposed on an interior of the door to provide actuation force to dispense blister reservoirs disposed on the cartridge when the door is closed, and a device disposed relative to the cartridge to move at least a portion of contents of the cartridge among chambers of the cartridge.

Methods and Treatment Involving Excess Free LIGHT

Resumen de: US20260085112A1

The present disclosure relates to methods of detecting free (active) LIGHT in biological samples to diagnose conditions associated with elevated free LIGHT, as well as to predict the effectiveness of anti-LIGHT therapies. The disclosure also relates to treating such conditions with anti-LIGHT antibodies. Conditions include acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), optionally wherein the ALI and ARDS are associated with viral infection, including coronavirus infection. Conditions also include Crohn's Disease or an inflammatory condition associated with Crohn's Disease.

METHODS OF TREATING ALZHEIMER'S DISEASE

Nº publicación: WO2026064441A1 26/03/2026

Solicitante:

OTHAIR PROTHENA LTD [IE]
ALBRECHT JIRI [US]
QUADRINI KAREN J [US]
VERNHES FREDERIQUE [US]
OTHAIR PROTHENA LIMITED,
ALBRECHT, Jiri,
QUADRINI, Karen, J,
VERNHES, Frederique

Resumen de: WO2026064441A1

The disclosure is related to methods of treating a subject with Alzheimer's Disease (AD) using anti-amyloid beta (Aβ) therapy. The patient may be treated based on the measurement and analysis of biomarker levels, such as plasma Aβ42/40 ratio, pTau181 and pTau217. The disclosure includes a systematic approach called CP Convert for converting biomarker measurements across different analytical platforms, enabling comparison of pTau217 data from LC-MS/MS, SIMOA, and chemiluminescent enzyme immunoassay platforms. Methods demonstrate that pTau217 has superior diagnostic accuracy compared to Aβ42/40 ratio and pTau181 for detecting brain amyloid positivity. Implementation of pTau217 prescreening can significantly reduce Aβ-PET testing, decreasing patient burden and clinical trial costs. The CP Convert methodology can be validated using independent cohorts, demonstrating robust cross-platform conversion for research applications.